Private Placement

A struggling medtech firm and an AI drug developer merge. It's not just a deal; it's a new blueprint for innovation, funded by high-risk capital.

Recent SEC filings link powerhouse investor Citadel to streaming upstart FreeCast. But as we peel back the layers, a story of high-risk, high-reward emerges.

A $17.5M write-down and a shareholder lawsuit reveal a critical lesson for tech firms: production capacity must align with market demand, or investors will pay the price.

A rapid $1.5M loan in Baldwin County isn't just a real estate deal. It's a signal of a massive economic shift fueled by billions in industrial investment.

AST SpaceMobile secured $1 billion via complex convertible notes to accelerate its global network, a strategic bet that spooks investors with dilution fears.

A Chinese firm aims to revolutionize cancer treatment with a cloud-based AI system, but faces a tough fight against industry giants and its own financial reality.

With stellar preliminary Q2 results, Virtu is also taking its term loan balance to nearly $2 billion. We look at the strategy behind the numbers.

High-grade gold discoveries at Wallbridge's Martiniere project are overshadowed by a wildfire-induced shutdown, a case study in modern mining's new risks.

Rithm Property Trust is raising cash to buy multifamily loans from its own manager. Is this a savvy move in a tough market or a risky inside deal?

Commodities giant Glencore transforms a $25M loan into a major equity position in Osisko Metals, signaling a strong bet on Canadian critical minerals.

With a new CMO, $50M in fresh capital, and pivotal trials on the horizon, Cue Biopharma makes a strategic bet on an immunology veteran to guide its future.

Riverside Resources is spinning out Ravena Resources, replicating a strategy that launched two other public companies. Is this a blueprint for success?

Alto Neuroscience's $100M raise fuels its quest to treat resistant depression. It's a high-stakes play on a biomarker-driven approach in a challenging field.

As BNB Plus Corp. falls from Nasdaq to the over-the-counter markets, its hybrid crypto-biotech model is under intense scrutiny. What does this mean for investors?

JZR Gold secured CAD$1M just as it seizes direct control of its Brazilian mill. Is this the final piece of the puzzle for production, or a dilutive lifeline?

The health-tech acquirer shores up its balance sheet with a $2.3M financing and debt deal, but a heavy reliance on insider transactions raises governance questions.

Serina Therapeutics' Parkinson's drug SER-252 advances, but the real story is its POZ Platform, a technology that could reshape drug delivery.

Fueled by a new $25M financing, Arras Minerals is doubling its drilling in Kazakhstan. A bold move to unlock a major copper-gold find, but not without risk.

Sivers Semiconductors pushed its earnings dates. This isn't a sign of trouble; it's the steep cost of admission to Wall Street's premier league.

A C$2M financing for Resouro's Tiros project isn't just about capital; it's a calculated move to de-risk a critical minerals asset in Brazil.